PerpEquities

Equity · Healthcare

Centene Corp. (CNC) perpetual futures

Centene is a US managed care company providing Medicaid, Medicare and commercial health insurance programs and services to under-insured families and organizations.

-2.4%NYSE closed
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NYSE:CNC

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

0/1 live markets
Venues
1
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
OI / float
-
Spot performance
1D-2.42%
5D+7.01%
1M+14.80%
6M+34.05%
YTD+80.24%
1Y+99.92%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeCNC-USDTWatchlist------USDT-
Best venues for this underlying

Best liquidity

-
No live data-

Tightest spread

-
No live data-

Highest volume

-
No live data-

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-27 · next report 2027-02-05 · Updated 155h ago
All financials →

Valuation & key figures

Market cap
$33.9B
Updated 155h ago
Revenue
$194.7B
Trailing 12 months
Revenue growth
+2%
Next fiscal year
Profit margin
+0.8%
P/E
23.1
Peer P/E 29.6
P/S
0.2
Peer P/E
29.6
Similar listed perps
Free cash flow
$4B
Trailing 12 months
Net income
$1.5B
Trailing 12 months
Revenue estimate
$198.6B
Next fiscal year
Earnings
2027-02-05
Revenue est. $45.8B · Updated 155h ago
Dividend
-
Revenue (TTM)$195B+4.8% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)0.6%+3.7 pp vs a year agoOperating income $1.19B
Net income (TTM)$1.46B+127.6% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$3.96B+18.0% vs a year agoCapex $781M
Diluted EPS (TTM)$2.92+127.0% vs a year agoSum of the last 4 quarters
Net cash$8.04B+386.3% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-27): revenue beat by 7.5%, EPS beat by 506.1%Revenue $50.6B vs $47.1B expected (+7.5%); EPS $0.58 vs $0.10 (+506.1%).
  • Revenue growth slowing: 1.9% year on yearQ3 '26 revenue $50.6B, against an average of 9.6% over the four quarters before.
  • Operating margin 0.6% (TTM), +3.7 pp on a year agoOperating income grew 120.8% while revenue grew 4.8%.
  • 38.1% of pre-tax profit is non-operatingPre-tax income $1.92B vs operating income $1.19B (TTM). Gains on equity stakes and other one-off items lift net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
Medicaid Segment$40.8B+9.3%80.6%
Medicaid–––
Commercial Segment$8.7B-20.9%17.2%
Medicare–––
Commercial–––
Other Operating Segment$1.1B-17.9%2.2%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 265 lines Centene Corp. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-05
Revenue est. $45.8B · Updated 155h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20265.19$198.6B+2%9
FY 20275.45$194B0%11
FY 20286.59$198.6B+2%5
FY 20298.60$202.6B+4%1
FY 20309.63$209.4B+7%1
Q1 20273.36$48.7B-2%9

Company events

6
2027-02-05EarningsActual - / Estimate -1.12-
2026-10-27Earnings · Before market openActual 0.58 / Estimate 0.1Beat
2026-07-28EarningsActual 2.51 / Estimate 1.09Beat
2026-04-28EarningsActual 3.37 / Estimate 2.23Beat
2026-02-06EarningsActual -1.19 / Estimate -1.22Beat
2025-10-29EarningsActual 0.5 / Estimate -0.14Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
ZTS$33.9B3.613.9+26.1%1ILMN$35.6B7.940.1+19.7%2DXCM$30.7B6.031.8+19.4%1BIIB$37.5B3.6107.5+3.4%4RVMD$38.1B192.7-19.4-946.8%1INSM$24.7B16.3-39.9-39.9%1BEIGENE$43.6B7.127.9+10.7%1WUXIBIO$23.4B6.631.2+21.2%5

Company data

Company intelligence

Updated: Nov 2, 2026, 05:16 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Healthcare Plans
Chief executive
Sarah McGinty London
Employees
61,100
IPO date
Dec 13, 2001
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei3.2
Piotroski scorei8/9
Overall ratingiB+
Owner earningsi-$3.84B-$7.77 per share
ESG risk ratingiB-Industry rank: 14 out of 15

Rating factors

Return on equityi
3
Return on assetsi
3
Debt to equityi
1
Price to earningsi
3
Price to booki
4

Company press releases

CENTENE CORPORATION REPORTS THIRD QUARTER 2026 RESULTSPRNewsWireAmbetter Health Announces 2027 Marketplace Offerings, Including Enhanced Condition-Specific Coverage OptionsPRNewsWireCENTENE CORPORATION TO HOST 2026 THIRD QUARTER FINANCIAL RESULTS EARNINGS CALLPRNewsWireCentene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and OklahomaPRNewsWirePA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive YearPRNewsWireCentene to Launch Nationwide Gold Card Program for Qualifying ProvidersPRNewsWire

Congressional disclosures

House

Market cap history
$32.49B+3.2%Aug 26 – Nov 26
$30.88B$32.58B$34.28BHigh: $34.28B · 2026-09-14Low: $30.88B · 2026-09-28Latest: $32.49B · 2026-11-02Aug 26Sep 26Oct 26Nov 26
Latest: $32.49B · 2026-11-02High: $34.28B · 2026-09-14Low: $30.88B · 2026-09-28
Largest fund holders
FundWeightShares held
VTI0.04%15.7M
VOO0.05%13M
VCPA.S0.14%7M
IVV0.05%6.6M
1657.T0.04%6.6M
XSP.TO0.05%6.6M
XWD.TO0.04%6.6M
VFLO3.32%6.1M
SPY0.05%6M
VSCA.S0.19%6M
FXAIX0.05%5.8M
VB0.19%5.6M

Analyst track record

How the analysts covering CNC have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings116325
Analysts2029
Buy / hold / sell53 / 58 / 5173 / 138 / 14
Upgrades / downgrades / initiations5 / 0 / 110 / 11 / 6
Price targets hit / missed63 / 44 (59%)125 / 174 (42%)
Avg. return after a rating (TipRanks)+19.6%+13.2%
Best / worst call+107.9% / -18.9%+137.6% / -39.5%

After buy calls on this stock: median 21-day move -0.1% vs S&P 500 -1.6% (n = 177)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. David S MacdonaldTruist Financial50% hit rate on this stock · 12 targets measuredBuytarget $82.00Nov 2, 2026
  2. David WindleyJefferies38% hit rate on this stock · 8 targets measuredHoldtarget $39.00Apr 20, 2026
  3. Lance WilkesBernstein33% hit rate on this stock · 15 targets measuredBuytarget $79.00Oct 5, 2026

Latest ratings

DateAnalystCallTarget
Nov 2, 2026David S MacdonaldTruist FinancialBuyMaintained$82.00article ↗
Oct 29, 2026John StanselJ.P. MorganHoldMaintained$75.00article ↗
Oct 29, 2026John StanselJ.P. MorganHoldMaintained$75.00article ↗
Oct 29, 2026Ryan LangstonTD CowenHoldMaintained$65.00article ↗
Oct 28, 2026Andrew Mok CFABarclaysBuyMaintained$82.00article ↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$30.00$40.00$50.00$60.00$70.00Dec 25 · Buy 4 · Hold 10 · Sell 3Dec 25Jan 26 · Buy 5 · Hold 10 · Sell 2Feb 26 · Buy 5 · Hold 10 · Sell 2Feb 26Mar 26 · Buy 5 · Hold 10 · Sell 2Apr 26 · Buy 6 · Hold 10 · Sell 1Apr 26May 26 · Buy 7 · Hold 9 · Sell 1Jun 26 · Buy 7 · Hold 10 · Sell 1Jun 26Jul 26 · Buy 8 · Hold 10 · Sell 1Aug 26 · Buy 9 · Hold 10 · Sell 1Aug 26Sep 26 · Buy 9 · Hold 10 · Sell 1Oct 26 · Buy 8 · Hold 9 · Sell 0Oct 26Nov 26 · Buy 8 · Hold 9 · Sell 0Dec 25 · avg. target $39.21Jan 26 · avg. target $42.57Feb 26 · avg. target $43.25Mar 26 · avg. target $42.44Apr 26 · avg. target $49.00May 26 · avg. target $54.07Jun 26 · avg. target $60.29Jul 26 · avg. target $67.11Aug 26 · avg. target $68.74Sep 26 · avg. target $68.84Oct 26 · avg. target $75.50Nov 26 · avg. target $75.50Dec 25 · month-end close $41.15Jan 26 · month-end close $43.32Feb 26 · month-end close $44.88Mar 26 · month-end close $32.74Apr 26 · month-end close $53.69May 26 · month-end close $59.60Jun 26 · month-end close $64.19Jul 26 · month-end close $62.22Aug 26 · month-end close $64.34Sep 26 · month-end close $62.12Oct 26 · month-end close $68.45Nov 26 · month-end close $68.45

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 3, 2026 · 116 ratings

Other Healthcare perps

Embed this asset

CNC perpetuals · perpequities.comCNC perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/cnc-perp"><img src="https://perpequities.com/badge/cnc-perp.svg" width="240" height="64" alt="CNC perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of CNC perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for CNC — one email every Sunday.

Watchlist and alerts

Price and funding alerts for CNC, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X